Citi raised the firm’s price target on Establishment Labs (ESTA) to $43 from $40 and keeps a Neutral rating on the shares. The firm is cautious on medical technology entering the Q3 earnings season. Citi believes the outcome of the Section 232 investigation into medical equipment and devices will take time.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs Amends Credit Agreement with Oaktree
- Establishment Labs initiated with a Buy at Canaccord
- Establishment Labs Reports Strong Growth Amid Challenges
- Establishment Labs Reports Strong Q2 2025 Revenue Growth
- Establishment Labs Holdings: Strong Financial Performance and Promising Market Trends Justify Buy Rating